China Develops New Inhibitor to Overcome the Drug Resistance Mutation of Acute Myeloid Leukemia
Liao Shumin
DATE:  Oct 23 2017
/ SOURCE:  Yicai
China Develops New Inhibitor to Overcome the Drug Resistance Mutation of Acute Myeloid Leukemia China Develops New Inhibitor to Overcome the Drug Resistance Mutation of Acute Myeloid Leukemia

(Yicai Global) Oct. 23 -- A research group led by Liu Qingyun and Liu Jing of High Magnetic Field Laboratory of the Hefei Institutes of Physical Science of the Chinese Academy of Sciences recently developed a new kinase inhibitor II able to overcome the drug resistance mutation of acute myeloid Leukemia, and an inhibition rate of up to 97 percent has been registered in the rodent laboratory.

The American Chemical Society's Biochemistry published the results, official Xinhua News Agency reported.

Acute myeloid leukemia poses a grievous threat to human health. Research results show that 30% of incidences result from mutations of FLT3 kinase, and now great achievements have come in the research and development of inhibitors centered upon this kinase inhibitor, but the problem of drug resistance also arises, so targeted therapy against the second mutation has become a research hotspot.

The compound has a marked inhibitory effect on the proliferation of various cells of FLT3-ITD mutation, and had an obvious effect on the apoptosis of these cells, the results showed.

Follow Yicai Global on
Keywords:   Chinese Academy of Sciences,Acute Myeloid Leukemia,Resistance Mutation